摘要
Allogeneic stem cell transplantation (SCT) is a standard therapy for hematological malignancies. Stable immunotolerance format ion is the base for the successful transplantation. An important benefit of allo geneic SCT is the graft-versus-leukemia (GVL) effect. However, GVL effects are closely linked with grate-versus-host disease at present, a major cause of mo rbidity and mortality after allogeneic SCT. With the improved understanding of m olecular mechanism for all those phenomena, it is possible to separate GVL from GVHD and improve the overall survival of allogeneic SCT for hematological malign ancy. New and innovative immunotolerance methods will be developed in the near f uture and open a new era for mismatched allogeneic SCT.
Allogeneic stem cell transplantation (SCT) is a standard therapy for hematological malignancies. Stable immunotolerance format ion is the base for the successful transplantation. An important benefit of allo geneic SCT is the graft-versus-leukemia (GVL) effect. However, GVL effects are closely linked with grate-versus-host disease at present, a major cause of mo rbidity and mortality after allogeneic SCT. With the improved understanding of m olecular mechanism for all those phenomena, it is possible to separate GVL from GVHD and improve the overall survival of allogeneic SCT for hematological malign ancy. New and innovative immunotolerance methods will be developed in the near f uture and open a new era for mismatched allogeneic SCT.
出处
《基础医学与临床》
CSCD
2000年第6期500-504,共5页
Basic and Clinical Medicine
关键词
造血干细胞移植
免疫问题
移植免疫学
allogeneic stem cell transplantation； imm unotolerance； graft-versus-leukemia
graft-versus-host disease, hematologic al malign anices
